Daniel Karlin News Today

Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States Phong...

Jim Cramer recently hyped up one of his guests in advance of his CNBC show "Mad Money," posting on X that people "will be very interested in MindMed for certain ... LSD," and he made sure his interview did not disappoint. Mind Medicine Inc. (NASDAQ:MNMD) sees a massive market opportunity ahead, citing 21% of U.S. adults with an anxiety disorder, an estimated 4.4% of U.S. adults with attention-deficit/hyperactivity disorder (ADHD) and a $461 billion economic cost from autism s...

This March 2024 psychiatry month in review highlights positive phase 2b and phase 2a data for drugs targeting treatment-resistant depression, generalized anxiety disorder, and PTSD.

Studies show benefits for people with high anxiety, depression, and PTSD, but there are questions about how these drugs might be used.

New research shows that a form of LSD may be an effective treatment for generalized anxiety disorder, with the FDA designating the drug as a breakthrough therapy.

A phase 2 clinical trial showed that MM-120 — a hallucinogen better known as LSD — could be effective in treating generalized anxiety disorder.

A lead candidate psychedelic drug developed by the US company MindMed has shown the potential to treat generalized anxiety disorder in a phase 2b trial.

A phase 2b clinical trial met its primary endpoint with positive topline results, showing MM-120 (lysergide d-tartrate) can reduce symptoms of generalized anxiety disorder, reflected in the Hamilton Anxiety rating scale scores.

Valley Drive has been under construction this summer—viewer Jennifer Vieth wanted to know what was going on with the project and if it would be done in time for the first day of school.